FOI 0418 2019/20 Security/RPI Teams
Published: October 18, 2019
Freedom of Information Request: 0418 2019/20 Do you have an internal or external RPI/Security team? Security staff employed by the Trust are all external bought in under contract. Do these staff wear stab vests? All security staff on all sites wear stab vests Do they use/wear body worn cameras/video? Only security at QE use body […]
FOI 0410 2019/20 Thrombolysis and Thrombectomy Trust Guidelines
Published: October 18, 2019
Freedom of Information Request: 0410 2019/20 We understand from your Trust’s guideline CG009 ‘Thrombolysis and Thrombectomy’ version 3.1 that at the time of the policy there was an out of hours thrombectomy service provided on a case-by-case basis and the expectation a full 24 hour thrombectomy service would be in place in 2017. Please would […]
FOI 0405 2019/20 Ursodeoxycholic Acid Capsules
Published: October 18, 2019
Freedom of Information Request: 0405 2019/20 Has the pharmacy of your hospital(s) dispensed Ursodeoxycholic Acid 250mg capsules between the following periods?: from September 1, 2017 till August 31, 2018 from September 1, 2018 till August 31, 2019 2. If the answer is ‘yes’ to request 1, could you please send me details in […]
FOI 0396 2019/20 Ground Maintenance and Gardening Service Contracts
Published: October 18, 2019
Freedom of Information Request: 0396 2019/20 Under the Freedom of information Act 2000, please will you provide the following details relating to ground maintenance and gardening service contracts given out or awarded by the NHS (West Midlands): What was the annual budget for contract ground maintenance and gardening services undertaken at each of the […]
FOI 0392 2019/20 Informatics Department
Published: October 18, 2019
Freedom of Information Request: 0392 2019/20 1. What is the size of your informatics team (FTE)? 2. What percentage of time is spent on workforce/employee reporting (as compared with clinical reporting etc.) 2a. of the workforce/employee reporting, what is the estimated time split between standard and non-standard (custom) reporting. (examples of standard reports could include […]
FOI 0375 2019/20 G Cloud Procurement Strategies
Published: October 18, 2019
Freedom of Information Request: 0375 2019/20 I hope you can help me with an exercise we are conducting, to understand more about the Procurement Strategies in the Public Sector; specifically within Local Authorities and around the take up of G Cloud. The information you provide as part of this Freedom of Information exercise will help […]
FOI 0373 2019/20 OCD Treatment in CAMHS
Published: October 18, 2019
Freedom of Information Request: 0373 2019/20 Do you provide CAMHS (Child and adolescent mental health service)? No If you do offer CAMHS, what is the age threshold for people receiving OCD treatment within CAMHS? Not Applicable In addition, what measures do you have in place for transitioning from CAMHS to […]
FOI 0370 2019/20 Intravitreal Vials/Implants
Published: October 18, 2019
Freedom of Information Request: 0370 2019/20 Within your trust how many of the following intra-vitreal vials/implants have been used in the latest 4 months, if possible between May to August 2019; Aflibercept 1729 Bevacizumab 191 Dexamethasone 107 Fluocinolone 4 Ranibizumab 1802
FOI 0369 2019/20 Gynaecology Cancer
Published: October 18, 2019
Freedom of Information Request: 0369 2019/20 Does your Trust have a straight to test gynaecology pelvic ultrasound pathway prior to two week wait cancer referral to exclude endometrial cancer. No, we do not have the ability to exclude endometrial cancer by scan, we have a see and treat clinic. If yes, was this agreed with […]
FOI 0366 2019/20 Metastatic Differentiated Thyroid Cancer Treatment
Published: October 18, 2019
Freedom of Information Request: 0366 2019/20 In the past 12 months, how many patients with metastatic differentiated thyroid (refractory to radioactive iodine) cancer were treated with: Axitinib Cabozantinib Lenvantinib Pazopanib Sorafenib Sunitinib Vandetanib 2. In the past 12 months, how many metastatic Renal Cell Carcinoma patients were treated with: Sunitinib Pazopanib Everolimus Temsirolimus Cabozantinib Nivolumab […]
